D027 OA 1 Actual Exam V2 | D027 Advanced Pathopharmacology
(D027 OA 1) | Western Governors University PDF
1. A patient with chronic kidney disease is prescribed a drug that is primarily eliminated via
renal excretion. How should the initial dosing strategy be adjusted to maintain therapeutic
levels while avoiding toxicity?
A. Decrease the dose or increase the dosing interval.
B. Increase the loading dose to reach steady state faster.
C. Switch to an oral formulation to slow absorption.
D. Administer the drug with a high-protein meal.
Answer: A
Rationale: In patients with impaired renal function, the clearance of drugs eliminated by
the kidneys is significantly reduced. Adjusting the dose downward or extending the time
between doses prevents the accumulation of the drug to toxic levels. This evidence-based
approach is critical in graduate-level medication management for geriatric and renal
populations.
2. A patient is identified as a ‘poor metabolizer’ of CYP2D6 via pharmacogenomic testing.
What is the most likely clinical implication when prescribing Codeine for pain management?
A. The patient will experience enhanced analgesic effects.
B. The patient will be at high risk for respiratory depression.
C. The patient will experience little to no pain relief.
D. The patient will metabolize the drug faster than normal.
Answer: C
Rationale: Codeine is a prodrug that must be converted into its active metabolite,
morphine, by the CYP2D6 enzyme. Poor metabolizers lack sufficient enzyme activity to
perform this conversion, resulting in subtherapeutic levels of the active drug.
Consequently, these patients do not receive adequate analgesia and require alternative
pain management strategies.
3. Which of the following describes the ‘First-Pass Effect’ in pharmacology?
A. The rapid distribution of a drug to highly vascularized organs.
B. The metabolism of an oral drug in the liver before it reaches systemic circulation.
C. The excretion of a drug through the biliary system into the feces.
D. The initial binding of a drug to plasma albumin proteins.
,Answer: B
Rationale: The first-pass effect occurs when an orally administered drug is absorbed from
the GI tract and enters the portal circulation. Before reaching the systemic bloodstream, the
drug passes through the liver, where a significant portion may be metabolized and
inactivated. This phenomenon explains why the bioavailability of oral drugs is often lower
than those administered intravenously.
4. A patient taking Warfarin (Coumadin) is prescribed Amiodarone for atrial fibrillation. What
is the expected pharmacokinetic interaction?
A. Amiodarone induces CYP2C9, decreasing the INR.
B. Amiodarone inhibits CYP2C9, increasing the risk of bleeding.
C. Amiodarone decreases the protein binding of Warfarin.
D. Amiodarone enhances renal clearance of Warfarin.
Answer: B
Rationale: Amiodarone is a potent inhibitor of the CYP2C9 enzyme, which is the primary
pathway for the metabolism of S-warfarin. Inhibition of this enzyme leads to higher plasma
concentrations of warfarin and a significant increase in the International Normalized Ratio
(INR). Clinicians must proactively reduce the warfarin dose and monitor coagulation
parameters closely when initiating amiodarone.
5. What is the primary mechanism of action of Lisinopril in the management of hypertension?
A. Blocking the binding of Angiotensin II to AT1 receptors.
B. Directly relaxing the smooth muscle of the peripheral vasculature.
C. Inhibiting the conversion of Angiotensin I to Angiotensin II.
D. Reducing the secretion of Renin from the juxtaglomerular cells.
Answer: C
Rationale: Lisinopril is an ACE inhibitor that prevents the Angiotensin-Converting Enzyme
from turning Angiotensin I into the potent vasoconstrictor Angiotensin II. By reducing
Angiotensin II levels, lisinopril also lowers aldosterone secretion, which decreases sodium
and water retention. This dual action effectively reduces systemic vascular resistance and
blood pressure.
6. A patient on Digoxin therapy presents with nausea, blurred vision, and a heart rate of 48
bpm. Which electrolyte abnormality most significantly increases the risk of this toxicity?
A. Hypokalemia
B. Hypocalcemia
C. Hyperkalemia
, D. Hypernatremia
Answer: A
Rationale: Hypokalemia increases the sensitivity of the cardiac muscle to digoxin because
potassium and digoxin compete for binding sites on the Na+/K+ ATPase pump. When
potassium levels are low, more digoxin binds to the pump, leading to excessive inhibition
and toxic effects. Monitoring serum potassium is a vital component of advanced medication
management for patients on cardiac glycosides.
7. Which pharmacological parameter determines the time required to reach steady-state
plasma concentrations?
A. The drug’s elimination half-life.
B. The volume of distribution (Vd).
C. The rate of drug absorption.
D. The therapeutic index of the drug.
Answer: A
Rationale: Steady state is achieved when the rate of drug administration equals the rate of
drug elimination. It typically takes approximately four to five half-lives for a drug to reach
steady-state concentrations. This principle holds true regardless of the dose amount,
provided the dosing interval remains constant.
8. Why are drugs with a narrow therapeutic index (NTI) particularly challenging to manage?
A. They are rapidly metabolized by the liver.
B. The difference between the effective dose and the toxic dose is small.
C. They have a very high volume of distribution.
D. They require high loading doses to be effective.
Answer: B
Rationale: Drugs with a narrow therapeutic index have a small window between the
concentration needed for efficacy and the concentration that causes toxicity. Minor
fluctuations in plasma levels due to drug interactions or patient physiological changes can
lead to serious adverse events. Frequent therapeutic drug monitoring (TDM) is usually
required for these medications, such as lithium or phenytoin.
9. A patient is diagnosed with Type 2 Diabetes and has a GFR of 25 mL/min. Why is
Metformin contraindicated in this patient?
A. It causes significant weight gain in renal patients.
B. It is highly protein-bound and will not be filtered.
(D027 OA 1) | Western Governors University PDF
1. A patient with chronic kidney disease is prescribed a drug that is primarily eliminated via
renal excretion. How should the initial dosing strategy be adjusted to maintain therapeutic
levels while avoiding toxicity?
A. Decrease the dose or increase the dosing interval.
B. Increase the loading dose to reach steady state faster.
C. Switch to an oral formulation to slow absorption.
D. Administer the drug with a high-protein meal.
Answer: A
Rationale: In patients with impaired renal function, the clearance of drugs eliminated by
the kidneys is significantly reduced. Adjusting the dose downward or extending the time
between doses prevents the accumulation of the drug to toxic levels. This evidence-based
approach is critical in graduate-level medication management for geriatric and renal
populations.
2. A patient is identified as a ‘poor metabolizer’ of CYP2D6 via pharmacogenomic testing.
What is the most likely clinical implication when prescribing Codeine for pain management?
A. The patient will experience enhanced analgesic effects.
B. The patient will be at high risk for respiratory depression.
C. The patient will experience little to no pain relief.
D. The patient will metabolize the drug faster than normal.
Answer: C
Rationale: Codeine is a prodrug that must be converted into its active metabolite,
morphine, by the CYP2D6 enzyme. Poor metabolizers lack sufficient enzyme activity to
perform this conversion, resulting in subtherapeutic levels of the active drug.
Consequently, these patients do not receive adequate analgesia and require alternative
pain management strategies.
3. Which of the following describes the ‘First-Pass Effect’ in pharmacology?
A. The rapid distribution of a drug to highly vascularized organs.
B. The metabolism of an oral drug in the liver before it reaches systemic circulation.
C. The excretion of a drug through the biliary system into the feces.
D. The initial binding of a drug to plasma albumin proteins.
,Answer: B
Rationale: The first-pass effect occurs when an orally administered drug is absorbed from
the GI tract and enters the portal circulation. Before reaching the systemic bloodstream, the
drug passes through the liver, where a significant portion may be metabolized and
inactivated. This phenomenon explains why the bioavailability of oral drugs is often lower
than those administered intravenously.
4. A patient taking Warfarin (Coumadin) is prescribed Amiodarone for atrial fibrillation. What
is the expected pharmacokinetic interaction?
A. Amiodarone induces CYP2C9, decreasing the INR.
B. Amiodarone inhibits CYP2C9, increasing the risk of bleeding.
C. Amiodarone decreases the protein binding of Warfarin.
D. Amiodarone enhances renal clearance of Warfarin.
Answer: B
Rationale: Amiodarone is a potent inhibitor of the CYP2C9 enzyme, which is the primary
pathway for the metabolism of S-warfarin. Inhibition of this enzyme leads to higher plasma
concentrations of warfarin and a significant increase in the International Normalized Ratio
(INR). Clinicians must proactively reduce the warfarin dose and monitor coagulation
parameters closely when initiating amiodarone.
5. What is the primary mechanism of action of Lisinopril in the management of hypertension?
A. Blocking the binding of Angiotensin II to AT1 receptors.
B. Directly relaxing the smooth muscle of the peripheral vasculature.
C. Inhibiting the conversion of Angiotensin I to Angiotensin II.
D. Reducing the secretion of Renin from the juxtaglomerular cells.
Answer: C
Rationale: Lisinopril is an ACE inhibitor that prevents the Angiotensin-Converting Enzyme
from turning Angiotensin I into the potent vasoconstrictor Angiotensin II. By reducing
Angiotensin II levels, lisinopril also lowers aldosterone secretion, which decreases sodium
and water retention. This dual action effectively reduces systemic vascular resistance and
blood pressure.
6. A patient on Digoxin therapy presents with nausea, blurred vision, and a heart rate of 48
bpm. Which electrolyte abnormality most significantly increases the risk of this toxicity?
A. Hypokalemia
B. Hypocalcemia
C. Hyperkalemia
, D. Hypernatremia
Answer: A
Rationale: Hypokalemia increases the sensitivity of the cardiac muscle to digoxin because
potassium and digoxin compete for binding sites on the Na+/K+ ATPase pump. When
potassium levels are low, more digoxin binds to the pump, leading to excessive inhibition
and toxic effects. Monitoring serum potassium is a vital component of advanced medication
management for patients on cardiac glycosides.
7. Which pharmacological parameter determines the time required to reach steady-state
plasma concentrations?
A. The drug’s elimination half-life.
B. The volume of distribution (Vd).
C. The rate of drug absorption.
D. The therapeutic index of the drug.
Answer: A
Rationale: Steady state is achieved when the rate of drug administration equals the rate of
drug elimination. It typically takes approximately four to five half-lives for a drug to reach
steady-state concentrations. This principle holds true regardless of the dose amount,
provided the dosing interval remains constant.
8. Why are drugs with a narrow therapeutic index (NTI) particularly challenging to manage?
A. They are rapidly metabolized by the liver.
B. The difference between the effective dose and the toxic dose is small.
C. They have a very high volume of distribution.
D. They require high loading doses to be effective.
Answer: B
Rationale: Drugs with a narrow therapeutic index have a small window between the
concentration needed for efficacy and the concentration that causes toxicity. Minor
fluctuations in plasma levels due to drug interactions or patient physiological changes can
lead to serious adverse events. Frequent therapeutic drug monitoring (TDM) is usually
required for these medications, such as lithium or phenytoin.
9. A patient is diagnosed with Type 2 Diabetes and has a GFR of 25 mL/min. Why is
Metformin contraindicated in this patient?
A. It causes significant weight gain in renal patients.
B. It is highly protein-bound and will not be filtered.
